58
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Acetyl-CoA Carboxylase 1-Dependent Protein Acetylation Controls Breast Cancer Metastasis and Recurrence.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Breast tumor recurrence and metastasis represent the main causes of cancer-related death in women, and treatments are still lacking. Here, we define the lipogenic enzyme acetyl-CoA carboxylase (ACC) 1 as a key player in breast cancer metastasis. ACC1 phosphorylation was increased in invading cells both in murine and human breast cancer, serving as a point of convergence for leptin and transforming growth factor (TGF) β signaling. ACC1 phosphorylation was mediated by TGFβ-activated kinase (TAK) 1, and ACC1 inhibition was indispensable for the elevation of cellular acetyl-CoA, the subsequent increase in Smad2 transcription factor acetylation and activation, and ultimately epithelial-mesenchymal transition and metastasis induction. ACC1 deficiency worsened tumor recurrence upon primary tumor resection in mice, and ACC1 phosphorylation levels correlated with metastatic potential in breast and lung cancer patients. Given the demonstrated effectiveness of anti-leptin receptor antibody treatment in halting ACC1-dependent tumor invasiveness, our work defines a "metabolocentric" approach in metastatic breast cancer therapy.

          Related collections

          Author and article information

          Journal
          Cell Metab.
          Cell metabolism
          Elsevier BV
          1932-7420
          1550-4131
          Dec 05 2017
          : 26
          : 6
          Affiliations
          [1 ] Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; Technical University Munich, 85764 Neuherberg, Germany; Deutsches Zentrum für Diabetesforschung, 85764 Neuherberg, Germany.
          [2 ] Core Facility Tumor Models, German Cancer Research Center (DKFZ) and Medical Faculty Mannheim, Heidelberg University, 69120 Heidelberg, Germany.
          [3 ] Division of Vascular Oncology and Metastasis, German Cancer Research Center (DKFZ) and Medical Faculty Mannheim, Heidelberg University, 69120 Heidelberg, Germany.
          [4 ] Division Tumor Metabolism and Hypoxia, Bayer Health Care, 13353 Berlin, Germany.
          [5 ] Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; Technical University Munich, 85764 Neuherberg, Germany; Deutsches Zentrum für Diabetesforschung, 85764 Neuherberg, Germany. Electronic address: stephan.herzig@helmholtz-muenchen.de.
          [6 ] Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany; Technical University Munich, 85764 Neuherberg, Germany; Deutsches Zentrum für Diabetesforschung, 85764 Neuherberg, Germany. Electronic address: mauricio.berrieldiaz@helmholtz-muenchen.de.
          Article
          S1550-4131(17)30570-3
          10.1016/j.cmet.2017.09.018
          29056512
          bca9f1a1-f3e4-4226-a695-7e1406bc98ed
          History

          EMT,acetyl-CoA,acetylation,breast cancer,leptin,metastasis,pACC
          EMT, acetyl-CoA, acetylation, breast cancer, leptin, metastasis, pACC

          Comments

          Comment on this article